My watch list  

200 Current news of Evotec


You can refine your search further. Select from the filter options on the left to narrow down your results.

Evotec and Indivumed announce second joint drug discovery programme


Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). The final goal of this precision medicine collaboration is to deliver highly ...


Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome

Milestone payments potentially more than EUR 330 million


Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies will ...


Evotec and Bristol-Myers Squibb expand iPSC collaboration


Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to ...


Evotec receives € 3 million payment from Sanofi

Evotec achieves third milestone in cell therapy diabetes alliance with Sanofi


Evotec SE announced successful achievement of a third milestone in their diabetes research alliance with Sanofi (“TargetBCD”), resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. ...


Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse


Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Evotec has had a successful track record of managing Sanofi’s powder compounds at its Toulouse site since 2015. Under the terms of the new agreement, Sanofi will ...


Evotec expands strategic partnership with Celmatix


Evotec SE announced an expansion of the Company’s strategic partnership with Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics. Furthermore, together with investors including Life Sciences ...


image description
Merck Licenses CRISPR Gene-Editing Technology to Evotec

License to accelerate research, enable testing and development of new drugs


Merck announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines ...


Evotec and Vifor Pharma form joint venture


Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain ...


Evotec and Celmatix enter into strategic collaboration


Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, ...


Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian


Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective ...


Page 1 From 20
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE